{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T04:36:45Z","timestamp":1768883805312,"version":"3.49.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T00:00:00Z","timestamp":1562544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008546","name":"Diabetesf\u00f6rbundet","doi-asserted-by":"publisher","award":["DIA 2017-205"],"award-info":[{"award-number":["DIA 2017-205"]}],"id":[{"id":"10.13039\/501100008546","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["9321-430"],"award-info":[{"award-number":["9321-430"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002954","name":"Universit\u00e0 degli Studi di Milano-Bicocca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","award":["20120533"],"award-info":[{"award-number":["20120533"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","award":["KAW 2017.0203"],"award-info":[{"award-number":["KAW 2017.0203"]}],"id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2016-01527"],"award-info":[{"award-number":["2016-01527"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jacl.2019.06.011","type":"journal-article","created":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T11:36:26Z","timestamp":1562240186000},"page":"778-787.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Individuals with familial hypercholesterolemia and cardiovascular events have higher circulating Lp(a) levels"],"prefix":"10.1016","volume":"13","author":[{"given":"Chiara","family":"Pavanello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Pirazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Bjorkman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joakim","family":"Sandstedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Tarlarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"Mosca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Calabresi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosellina Margherita","family":"Mancina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2019.06.011_bib1","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1053\/euhj.2001.2842","article-title":"Coronary heart disease risk factors ranked by importance for the individual and community. A 21 year follow-up of 12 000 men and women from The Copenhagen City Heart Study","volume":"23","author":"Schnohr","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2019.06.011_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-153-3-201008030-00004","article-title":"Nonoptimal lipids commonly present in young adults and coronary calcium later in life: the CARDIA (Coronary Artery Risk Development in Young Adults) study","volume":"153","author":"Pletcher","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacl.2019.06.011_bib3","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2019.06.011_bib4","doi-asserted-by":"crossref","first-page":"a1095","DOI":"10.1136\/bmj.a1095","article-title":"Familial hypercholesterolaemia: summary of NICE guidance","volume":"337","author":"Wierzbicki","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2019.06.011_bib5","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1515\/CCLM.2005.134","article-title":"Familial hypercholesterolemia and response to statin therapy according to LDLR genetic background","volume":"43","author":"Choumerianou","year":"2005","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jacl.2019.06.011_bib6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.atherosclerosis.2014.01.054","article-title":"Lipoprotein(a) in various conditions: to keep a sense of proportions","volume":"234","author":"Kronenberg","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2019.06.011_bib7","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1172\/JCI114625","article-title":"Lipoprotein (a). Heterogeneity and biological relevance","volume":"85","author":"Scanu","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2019.06.011_bib8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10557-016-6648-3","article-title":"Human genetics and the causal role of lipoprotein(a) for various diseases","volume":"30","author":"Kronenberg","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacl.2019.06.011_bib9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10557-016-6654-5","article-title":"Future directions to establish lipoprotein(a) as a treatment for atherosclerotic cardiovascular disease","volume":"30","author":"Stein","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacl.2019.06.011_bib10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10557-015-6588-3","article-title":"PCSK9 inhibition: discovery, current evidence, and potential effects on LDL-C and Lp(a)","volume":"29","author":"Ferdinand","year":"2015","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacl.2019.06.011_bib11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.atherosclerosissup.2015.02.039","article-title":"Lipoprotein(a)\u2013An independent causal risk factor for cardiovascular disease and current therapeutic options","volume":"18","author":"Kassner","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.jacl.2019.06.011_bib12","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2019.06.011_bib13","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-8587(17)30088-8","article-title":"Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis","volume":"5","author":"Saleheen","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacl.2019.06.011_bib14","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1373\/clinchem.2017.276931","article-title":"High Lipoprotein(a) and low risk of major bleeding in brain and airways in the general population: a Mendelian randomization study","volume":"63","author":"Langsted","year":"2017","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2019.06.011_bib15","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacl.2019.06.011_bib16","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1056\/NEJM199005243222104","article-title":"Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia","volume":"322","author":"Seed","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2019.06.011_bib17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1046\/j.1365-2796.2003.01070.x","article-title":"Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia","volume":"253","author":"de Sauvage Nolting","year":"2003","journal-title":"J Intern Med"},{"key":"10.1016\/j.jacl.2019.06.011_bib18","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0002-9149(00)01429-6","article-title":"Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia","volume":"87","author":"Hopkins","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2019.06.011_bib19","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1373\/clinchem.2005.055228","article-title":"Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia","volume":"51","author":"Holmes","year":"2005","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2019.06.011_bib20","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","article-title":"Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation","volume":"63","author":"Alonso","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2019.06.011_bib21","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/joim.12263","article-title":"Genetic diagnosis of familial hypercholesterolaemia by targeted next-generation sequencing","volume":"276","author":"Maglio","year":"2014","journal-title":"J Intern Med"},{"key":"10.1016\/j.jacl.2019.06.011_bib22","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1194\/jlr.P072371","article-title":"Depletion in LpA-I:A-II particles enhances HDL-mediated endothelial protection in familial LCAT deficiency","volume":"58","author":"Gomaraschi","year":"2017","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2019.06.011_bib23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.atherosclerosissup.2017.07.002","article-title":"Spectrum of mutations in Italian patients with familial hypercholesterolemia: new results from the LIPIGEN study","volume":"29","author":"Pirillo","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.jacl.2019.06.011_bib24","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1161\/01.CIR.102.10.1082","article-title":"Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies","volume":"102","author":"Danesh","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2019.06.011_bib25","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/archinte.168.6.598","article-title":"Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data","volume":"168","author":"Bennet","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacl.2019.06.011_bib26","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1161\/STROKEAHA.106.480657","article-title":"Lipoprotein (a) and stroke: a meta-analysis of observational studies","volume":"38","author":"Smolders","year":"2007","journal-title":"Stroke"},{"key":"10.1016\/j.jacl.2019.06.011_bib27","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jacc.2013.09.042","article-title":"Lipoprotein(a) for risk assessment in patients with established coronary artery disease","volume":"63","author":"O'Donoghue","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2019.06.011_bib28","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2019.06.011_bib29","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.atherosclerosis.2011.02.007","article-title":"Lipoprotein(a) levels in coronary heart disease-susceptible and -resistant patients with familial hypercholesterolemia","volume":"216","author":"Nenseter","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2019.06.011_bib30","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1476-511X-10-94","article-title":"Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART)","volume":"10","author":"Mata","year":"2011","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jacl.2019.06.011_bib31","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1093\/clinchem\/46.12.1956","article-title":"Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a)","volume":"46","author":"Marcovina","year":"2000","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2019.06.011_bib32","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/clc.22880","article-title":"Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: between Scylla and Charybdis","volume":"41","author":"Ellis","year":"2018","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacl.2019.06.011_bib33","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1253\/circj.CJ-17-0392","article-title":"Clinical features and gaps in the management of probable familial hypercholesterolemia and cardiovascular disease","volume":"82","author":"Zafrir","year":"2017","journal-title":"Circ J"},{"key":"10.1016\/j.jacl.2019.06.011_bib34","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/01.ATV.20.2.522","article-title":"Lipoprotein(a) in homozygous familial hypercholesterolemia","volume":"20","author":"Kraft","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2019.06.011_bib35","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1034\/j.1399-0004.2001.590604.x","article-title":"LDL-receptor gene mutations and the hypocholesterolemic response to statin therapy","volume":"59","author":"Brorholt-Petersen","year":"2001","journal-title":"Clin Genet"},{"key":"10.1016\/j.jacl.2019.06.011_bib36","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0021-9150(97)00216-5","article-title":"Similar response to simvastatin in patients heterozygous for familial hypercholesterolemia with mRNA negative and mRNA positive mutations","volume":"136","author":"Sijbrands","year":"1998","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2019.06.011_bib37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0021-9150(97)00181-0","article-title":"Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolaemia. The Familial Hypercholesterolaemia Regression Study Group","volume":"136","author":"Sun","year":"1998","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2019.06.011_bib38","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2796.1995.tb01138.x","article-title":"Heterozygous familial hypercholesterolaemia: the influence of the mutation type of the low-density-lipoprotein receptor gene and PvuII polymorphism of the normal allele on serum lipid levels and response to lovastatin treatment","volume":"237","author":"Vuorio","year":"1995","journal-title":"J Intern Med"},{"key":"10.1016\/j.jacl.2019.06.011_bib39","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/j.1365-2362.1995.tb01975.x","article-title":"Is responsiveness to lovastatin in familial hypercholesterolaemia heterozygotes influenced by the specific mutation in the low-density lipoprotein receptor gene?","volume":"25","author":"Leren","year":"1995","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jacl.2019.06.011_bib40","first-page":"III35","article-title":"Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia","volume":"87","author":"Leitersdorf","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2019.06.011_bib41","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0021-9150(01)00584-6","article-title":"Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia","volume":"160","author":"Vohl","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2019.06.011_bib42","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1161\/01.ATV.18.6.1007","article-title":"Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia","volume":"18","author":"Couture","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2019.06.011_bib43","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.atherosclerosis.2013.12.028","article-title":"Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia","volume":"233","author":"Santos","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2019.06.011_bib44","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1210\/jcem.86.10.7899","article-title":"Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol","volume":"86","author":"Chaves","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2019.06.011_bib45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0021-9150(98)00274-3","article-title":"The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia","volume":"143","author":"Heath","year":"1999","journal-title":"Atherosclerosis"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287419302314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287419302314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:34:29Z","timestamp":1761831269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287419302314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1933287419302314"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2019.06.011","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Individuals with familial hypercholesterolemia and cardiovascular events have higher circulating Lp(a) levels","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2019.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}